Adocia to Hold Conference Call for Investors to Provide Business Update and Growth Perspectives

Wednesday September 21^st, 2016 at 6 PM (CET)

LYON, France--(BUSINESS WIRE)--Regulatory News:

Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 - ADOC) will provide a business update for investors and growth perspectives on a conference call to be held:

Wednesday September 21^st, 2016

at 6pm (CET)

Dial-in number: [phone]

The transcript will be available in French and in English on Adocia’s website

www.adocia.com

Please note that the conference call will be held in French.

The following speakers will conduct the call:

• Gérard Soula, President and CEO
• Olivier Soula, R&D Director & Deputy General Manager
• Valérie Danaguezian, CFO
• Rémi Soula, Director of Business Development & Intellectual Property

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.

The proprietary BioChaperone^® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Glucagon), combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide) and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.

Adocia aims to deliver “Innovative medicine for everyone, everywhere.”

To learn more about Adocia, please visit us at www.adocia.com